|
GB202101125D0
|
|
Antibodies and uses thereof
|
|
GB202017058D0
|
|
Antibodies and uses thereof
|
|
WO2020229621A1
|
|
Improved lambda antibodies
|
|
GB201919077D0
|
|
Improved lambda antibodies
|
|
TW202039584A
|
|
Fixaxfx bispecific antibody with common light chain
|
|
GB201917882D0
|
|
Treatment for physiological iron overload
|
|
GB201917524D0
|
|
Treatment for physiological iron overload
|
|
EP3806885A2
|
|
Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
|
|
GB201908190D0
|
|
Fixaxfx bispecific antibody with common light chain
|
|
GB201906816D0
|
|
FIXaxFX bispecific antibody with common light chain
|
|
GB201905552D0
|
|
Antagonists
|
|
GB201820977D0
|
|
Fixaxfx bispecific antibody with commomn light chain
|
|
GB201820687D0
|
|
Antagonists
|
|
US2020407446A1
|
|
Bispecific antibody for icos and pd-l1
|
|
GB201820215D0
|
|
Treatments etc
|
|
GB201815629D0
|
|
Antagonists
|
|
GB201814529D0
|
|
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
US2018362628A1
|
|
Anti-malarial antibodies that bind circumsporozoite protein
|
|
US2018295821A1
|
|
Transgenic Animals
|
|
US2019352413A1
|
|
Anti-opg antibodies
|
